Motesanib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Motesanib
Accession Number
DB05575
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
AMG 706 / AMG-706
Product Ingredients
IngredientUNIICASInChI Key
Motesanib diphosphateT6Q3060U91857876-30-3ONDPWWDPQDCQNJ-UHFFFAOYSA-N
Categories
UNII
U1JK633AYI
CAS number
453562-69-1
Weight
Average: 373.4509
Monoisotopic: 373.190260383
Chemical Formula
C22H23N5O
InChI Key
RAHBGWKEPAQNFF-UHFFFAOYSA-N
InChI
InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
IUPAC Name
N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboximidic acid
SMILES
CC1(C)CNC2=C1C=CC(=C2)N=C(O)C1=C(NCC2=CC=NC=C2)N=CC=C1

Pharmacology

Indication

Investigated for use/treatment in solid tumors.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Motesanib.
3,5-DiiodotyrosineThe therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Motesanib.
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Motesanib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Motesanib.
BenzylthiouracilThe therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Motesanib.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Motesanib.
DibromotyrosineThe therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Motesanib.
ElcatoninThe therapeutic efficacy of Elcatonin can be decreased when used in combination with Motesanib.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Motesanib.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Motesanib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
9842625
BindingDB
24773
ChEBI
51098
ChEMBL
CHEMBL572881
PharmGKB
PA166118340
HET
706
Wikipedia
Motesanib
PDB Entries
3efl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHistologically or Cytologically Documented Solid Tumors1
1CompletedTreatmentLocally Recurrent and Metastatic Breast Cancer1
1CompletedTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Solid1
1TerminatedTreatmentEsophageal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas1
1Unknown StatusTreatmentLung Cancers / Lymphoproliferative Disorders / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2WithdrawnTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Stage IV Breast Cancer1
2CompletedTreatmentAdvanced Gastrointestinal Stromal Tumors1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor / Neoplastic Syndrome1
2CompletedTreatmentGastrointestinal Cancers1
2CompletedTreatmentThyroid Cancers1
2TerminatedTreatmentAdvanced Non-squamous NSCLC1
2TerminatedTreatmentCancer, Breast / Locally Recurrent and Metastatic Breast Cancer / Neoplasms, Breast / Tumors, Breast1
2TerminatedTreatmentTumors, Solid1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00844 mg/mLALOGPS
logP3.48ALOGPS
logP2.91ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)5.45ChemAxon
pKa (Strongest Basic)7.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area82.43 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity115.53 m3·mol-1ChemAxon
Polarizability41.44 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolines
Direct Parent
Indolines
Alternative Parents
Nicotinamides / Secondary alkylarylamines / Aralkylamines / Aminopyridines and derivatives / Imidolactams / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids and derivatives
show 5 more
Substituents
Dihydroindole / Nicotinamide / Pyridinecarboxamide / Pyridine carboxylic acid or derivatives / Aminopyridine / Secondary aliphatic/aromatic amine / Aralkylamine / Imidolactam / Benzenoid / Pyridine
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyridinecarboxamide (CHEBI:51098)

Drug created on November 18, 2007 11:26 / Updated on June 04, 2019 06:18